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ABSTRACT
The number of aberrant splicing processes causing
human disease is growing exponentially and many
recent studies have uncovered some aspects of
the unexpectedly complex network of interactions
involved in these dysfunctions. As a consequence,
our knowledge of the various cis- and trans-acting
factors playing a role on both normal and aberrant
splicing pathways has been enhanced greatly.
However, the resulting information explosion has
also uncovered the fact that many splicing systems
are not easy to model. In fact we are still unable,
with certainty, to predict the outcome of a given
genomic variation. Nonetheless, in the midst of all
this complexity some hard won lessons have been
learned and in this survey we will focus on the
importance of the wide sequence context when
trying to understand why apparently similar muta-
tions can give rise to different effects. The examples
discussed in this summary will highlight the fine
‘balance of power’ that is often present between all
the various regulatory elements that define exon
boundaries. In the final part, we shall then discuss
possible therapeutic targets and strategies to res-
cue genetic defects of complex splicing systems.
INTRODUCTION
The study of the connections between defective splicing and
occurrence of disease has become a central issue in the medi-
cal research ﬁeld (1–7). This is a consequence of the growing
list of pathological alterations that can be directly linked with
aberrant splicing processes. In fact, for many genes, genomic
variations which affect the splicing process may represent up
to 50% of all mutations that lead to gene dysfunction (8,9).
This awareness has also led to the critical reappraisal of
many past observations, and it is now clear that substitutions
which had for a long time been regarded as harmless synony-
mous changes in protein coding regions may have some very
severe consequences on splicing processes, and thus on the
appearance of disease (10).
The underlying biological reason for such an exuberant
growth in the number of diseases derived from splicing
derangements is due not only on the intrinsic properties of
the exon itself (presence of regulatory elements within the
exon, strength of the splice sites etc.) but also on the wider
environment within which the exon is found, such as the pres-
ence of regulatory elements dispersed throughout the gene at
much longer distances (11–14), the splicing events that have
taken place before the exon of interest (15,16) or the type
of promoter architecture and the consequent polymerase II
processivity (17). This means that splicing spoilers can
occur virtually everywhere within any given gene and many
of the novel types of mutations identiﬁed have still poorly
characterized functional mechanisms (18). Furthermore,
alternative splicing processes (19) are responsible for increas-
ing the functional diversity of the human genome (20–24).
Therefore, it is very likely that variations anywhere in the
genome may alter the delicate modulation of the splicing pro-
cess and produce pathological alterations (3).
Numerous methodological developments have also aided
researchers recently in the task of building connections
between splicing and disease. For example, the reﬁnement of
minigene-based technologies for alternative splicing analysis
initially described 20 years ago (25) has allowed a relatively
fast approach to identify splicing spoilers and to study their
underlying functional mechanisms (26,27). In addition, a
great boost for the preliminary identiﬁcation of general splic-
ing regulatory sequences (SREs) has been the development
of SELEX methodologies to characterize binding speciﬁcities
of trans-acting factors involved in splicing regulation (28,29).
Last but not least, scientiﬁc interest in this subject has
also been steadily growing as potential applications in the
molecular therapy ﬁeld have begun to be appreciated and
have started to be tested, such as the recent advances in the
use of bi-functional or inhibitory oligonucleotides in rescuing
aberrant splicing events (3,30–35), in the engineering of
speciﬁc compounds by chemical synthesis to target splicing
factor protein families (36–38), or in the development of
novel vectors based on U7snRNA to rescue protein function-
ality by exon skipping (39).
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mRNA sequence away from the canonical AG/GU
nucleotides at the splice junctions are ever more frequently
been described as capable of affecting the splicing process
(40) was rather unexpected. Indeed, computational analyses
conﬁrm that when most of the main determinants of exon
deﬁnition (30ss, 50 ss, branch site and pY tract) are close to
the consensus minimal variations may be possible without
impairing recognition by the spliceosome (41). This conclu-
sion is also consistent with the rather loose sequence-
speciﬁcities of many essential splicing factors. For example,
in vitro studies have shown that a minimal amount of all
the potential base pairings between the 50 splice site and
U1snRNA is sufﬁcient for its correct recognition by
U1snRNP (42). Moreover, even in the absence of the 50 tail
of U1snRNA, the U1snRNP particle is capable of selecting
a5 0ss-like sequence probably through the U1-C subunit
(43). Finally, the observation that over-expression of SR pro-
teins could compensate for absence of U1snRNP in vitro
(44,45) provides support to the view that the splicing process
can be precise even in the absence of key participants.
Reality, however, has painted a much more complex
picture, with the micro-environment having an important
role in the ability of a splice site to tolerate a nucleotide
transition (46). Furthermore, microarray technology and com-
parative expressed sequence tags analyses are now vividly
depicting a world of widespread differences in alternative
splicing levels, both within normal tissues or following
pathological alterations (47–49). For this reason, particular
effort has been devoted recently to characterize splicing
abnormalities in cell transformation and cancer (50,51) as
they may provide an additional therapeutic target for this
kind of diseases.
The fact that splicing regulation appears to be a linked net-
work (52–56) means that researchers and clinicians have to
consider as a potential splicing mutation virtually every sub-
stitution that is encountered within a pre-mRNA sequence
(18). The recent evidences that many splicing factors may
also be actively involved in other important cellular pro-
cesses, such as genome stability (57) or mRNA transport
and translation (58–61), have just begun to unravel all the
connections of the RNA processing system (62,63). In fact,
rather than becoming simpliﬁed, splicing regulation in the
new millenium could be best characterized as right on the
edge of chaos. Figure 1 shows a simpliﬁed view of how
the number of accepted players and functions have grown
in recent years. It is for this reason that the connotation of
‘difﬁcult to characterize’ is increasingly associated with
many new splicing mutations.
The following observations exemplify the problems that
the molecular machinery has to resolve to obtain proper
splicing:
  Potential exon boundaries are particularly abundant in pre-
mRNA molecules. For example, in the human hprt gene
there are  10 times more consensus splice site than those
effectively recognized by the splicing machinery (64),
  The splicing process occurs in a background of repression,
as random human genomic sequences display a higher
than average splicing inhibitory activity when tested in
minigene systems (65–67),
  Positive or negative SREs are abundant in all pre-mRNAs,
both within introns and exons regardless if they are
constitutively or alternatively spliced (67–69).
  All the processes that deal with an RNA life cycle
including transcription, splicing, transport, translation and
degradation are no longer considered as separated from
Figure 1. The three schematic representations show the increase during the
last decade of the number of interactions reported to occur during RNA
processing. The upper diagram depicts a classic pre-mRNA molecule in
which the exon (closed box) is defined by a small number of relatively
conserved sequences that bind a well-defined set of basic splicing factors. The
complexity of the system begins to increase, as shown in the middle diagram,
when the vast and still growing array of enhancer and silencer factors are to
be added to the basic picture. These factors can bind particular enhancer
and silencer sequences either within the exon itself (ESE and ESS) or in the
nearby flanking regions (ISE and ISS) and help increase/decrease exon
recognition. As shown in the bottom diagram, in these recent years the
complexity of the regulatory elements that participate in splicing control has
taken an enormous leap forward by the discovery of the potential connections
between splicing, the specific structural features of pre-RNAs and many of
the processes that participate in a their life-cycle such as genome stability,
RNA processing speed, transport and translation.
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the Latin word ‘complexus’, appear to be functionally
entwined/twisted together (54,70,71). Indeed, just how
close relationships within the spliceosome can grow is
clearly highlighted by the recent demonstration of exten-
sive molecular tethering between the pre-mRNA being
processed and the splicing machinery, allowing processing
to occur correctly even when the nucleotide chain of the
pre-mRNA molecule is interrupted (72).
As a consequence, the sequence and genomic ‘context’ in
which mutations are observed to occur are essential to explain
the sometimes widely different outcomes of similar substitu-
tions in different genes (18,55). Several excellent articles
have reviewed the individual connections between aberrant
splicing and disease in recent years (1–7). Our purpose will
be that of using selected examples to highlight the importance
of genomic and local context when investigating splicing out-
comes. For example, the inactivation of donor site (50ss)
sequences produce a great variety of splicing outcomes that
vividly depicts the mind boggling variety of exon/intron
deﬁnition mechanisms.
WHAT MAY HAPPEN WHEN A DONOR SITE
IS INACTIVATED?
The recognition of the donor site is one of the key events of
the splicing process (73), and many of its peculiarities are still
under investigation (42,43,74–76). Mutations that destroy
natural donor sequences are usually observed to cause the
skipping of their associated exon (77). However, in a consid-
erable number of cases additional events can also take place,
which include cryptic splice site activation and full intron
inclusion. Now, whether any of these events takes place or
not is often dependent on the individual context in which
the substitution occurs. Sometimes evaluating this context
may be fairly straightforward; however, in some cases it
may also involve long-range genomic context interactions
or be dependent on some kind of ‘priming’ effect to the splic-
ing machinery by events happening upstream of the exon in
question (see below).
Cryptic splice site activation
Activation of cryptic splice sites is probably the most promi-
nent outcome (after exon skipping) that follows the inactiva-
tion of the original donor site. In fact, cryptic splice site
activation in the b-globin gene was one of the ﬁrst medically
relevant splicing defects described (78,79). The usage of
alternative splice sites following the inactivation of the proper
site often leads to a frameshift in the protein coding sequence.
It should be noted, however, that cryptic splice site sequences
do not simply represent a harmful background to normal
splicing pathways. Rather, it is now increasingly clear that
they have played a very important role in the still very
much debated evolutionary mechanisms of intron gain/loss
(80) and recent work has suggested that in some cases they
act as preferential sites for intron insertion (81,82).
Following the disruption of the normal donor site it would
be convenient to predict beforehand which sites (if any)
become activated by simply looking at all the nearby
sequences that match the consensus. In practice, however,
there is not always a straight correlation between the
chosen cryptic site and the calculated strength of the potential
sites in the region (83). Contemporary studies on donor (83)
and acceptor sites (84) have established that local context
features may help the splicing machinery to actively dis-
criminate against the usage of cryptic sites and in favor of
natural 50 and 30ss. These local context features may play a
role in cryptic splice site usage after disruption of the natural
site.
For example, SR protein levels have been long known to
affect relative cryptic splice site usage in the human b-globin
gene both in vitro and in vivo (85,86). Now, two recent
reports have demonstrated a critical role of SR-binding
sequences on cryptic splice site selection: in the E1a Pyru-
vate Dehydrogenase pre-mRNA a single point mutation
away from the natural ss strengthens a weak, pre-existing
SC35-binding site and has the effect of shifting donor site
usage to a previously silent cryptic site (87) (Figure 2A).
This mutation has an important biological impact and is
linked with mental retardation. In the second case, a strong
SF2/ASF-binding region in ﬁbrinogen exon 7 which is not
normally needed for constitutive inclusion of this exon in
the mature mRNA has the ability to determine an increase
in the relative usage levels of a particular cryptic donor site
when the natural donor site is inactivated by a IVS7 + 1G
> U mutation (88). Interestingly, changing the local context
by swapping the native SF2/ASF-binding sequence with a
different SR-binding ESE sequence from the ﬁbronectin
gene (fnESE) has the ability to change the relative cryptic
site usage ratios with respect to the natural ﬁbrinogen
sequence (Figure 2B).
Finally, an additional general factor that has been
described to affect cryptic splice site usage is represented
by RNA secondary structure (12–14,89). For example, in
the early region 3 of adenovirus type 2 a stem–loop structure
allows the correct and exclusive usage of its D1 natural donor
site rather than a cryptic donor site (Dcr1) located 74 nt
away (90,91) (Figure 2C). Disruption of this structure results
in a shift towards the Dcr1 site.
Intron retention
An intron retention event is identiﬁed as the preservation
of an entire intronic sequence within some forms of the
ﬁnal processed mRNA. Using this criteria, the frequency of
normal intron retention events in the human genome has
been estimated recently to be  15% in a set of >21000 anno-
tated genes (92). Most of these events naturally occur in the
untranslated regions of the pre-mRNA where the rate of
retention is observed to be >10-fold greater with respect to
protein coding sequence (92). The biological role of most
of these events is currently unknown; however, retained
introns within the coding region are signiﬁcantly shorter
than non-retained introns (92,93). Furthermore, their
sequences are under selective pressure for coding potential
(92), suggesting a potentially regulatory role in protein func-
tions. In recent years, the biological signiﬁcance of some
physiological intron retention events has also been clearly
established in several cases such as the generation of the
P element and Msl2 transcripts in Drosophila (94,95) or in
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RNA in chicken embryos (96).
Most importantly, aberrant intron retention events have
also been shown to be associated with several pathological
splicing defects. For example, in the Ret tyrosine kinase
gene (97) where it has been connected with the presence of
pheocromocytomas, in the HERG gene where it has been
identiﬁed as being responsible for the development of a
long QT syndrome (LQT2 phenotype) in an individual
which carried a +6T > C mutation in the donor site of intron
7 of this gene (98) and in a patient affected by Leigh
syndrome where the retention of intron 3 in the SURF1
gene follows a single-nucleotide mutation in its donor site
(99). As similar mutations in other contexts cause exon skip-
ping it is highly probable that local context features either in
the retained intron itself or in the ﬂanking exonic sequences
determine this particular outcome. At the moment, very little
is known concerning this issue and it is to be hoped that
future studies will target these particular issues.
An interesting phenomenon that also deals with intron
retention/recognition has been observed by analyzing the
last exon of the TPO gene. In 26% of the TPO transcripts a
116 n sequence located in the last exon is removed and
hence treated as an ‘alternative intron’ (Figure 3A, upper
panel) (15). Strikingly, this short intron behaves as such
only if there has been an upstream splicing event. In fact, if
the cDNA of the TPO gene is transfected in Hep3B cells
removal of the 116 nt intron is completely abolished
(Figure 3A, lower panel). The recognition of the small intron
50 and 30ss within TPO’s last exon seems to require spliceo-
some assembly on a previous intron, as the effect is obtained
not only with the intact intron structure of the TPO gene but
also by inserting any single intron in the cDNA sequence
(Figure 3B). Although the mechanism responsible for these
Figure 2. (A) Schematic diagram showing how local context arrangements can influence cryptic splice site activation. For example, in intron 7 of the PDH gene
a G26A mutation greatly enhances a preexisting binding site for the SC35 protein (upper and middle panels). The increased binding of this protein causes the shift
of donor site usage towards a cryptic donor site in the downstream sequence (lower panel). (B) Another example is represented by a strong SF2/ASF-binding
sequence that is not normally needed by the splicing machinery to recognize fibrinogen exon 7 (upper panel). However, if the natural donor site is inactivated by
a +1G > U substitution the relative usage of the three cryptic sites which become activated (c1, c2 and c3) and the levels of exon skipping (es) are profoundly
influenced by its presence, especially c1 (middle panel). In this case, the importance of local context has also been demonstrated by replacing the natural SF2/
ASF-binding sequence with a well-known ESE sequence from the fibronectin gene (fnESE) and observing that the level of c1 usage are substantially increased
with respect to the natural sequence (lower panel). (C) Finally, in the case of RNA secondary structure it has been shown that correct utilization of the natural
donor site sequence (D1) can be achieved only in the presence of a highly conserved stem-loop structure within Adenovirus type 2 first exon (upper panel).
Removal of this sequence has the consequence of activating usage of a cryptic donor site sequence (Dcr1) (lower panel).
Nucleic Acids Research, 2006, Vol. 34, No. 12 3497coordinated intron recognition events is currently unknown, it
is clear that some kind of ‘priming’ event from the splicing
machinery may be required for the processing of this intron.
Intriguingly, a somewhat analogous mechanism, this time on
exon recognition, has been proposed recently to exist in the
coordination of splicing between two independent alterna-
tively spliced regions within a ﬁbronectin minigene (16)
(Figure 3C). In this case, mutations that inhibit inclusion of
the proximal exon (pEDA) correlate directly with inclusion
levels of the distal exon (dEDA). Furthermore, existence of
such a phenomenon has also been described in vivo in a
mouse knock-in model (100) between two different alterna-
tively spliced regions of the ﬁbronectin gene (the EDA
exon and the V region) (16).
These examples, together with the recent description of
connections between chromatin factors (101), promoter
usage and transcript elongation on the splicing process
(17,102) clearly highlight how difﬁcult it is to separate the
functional effect of a given nucleotide variation from its
wide genomic context, and further examples of connections
between the upstream history of the transcription/splicing
machinery and downstream exon deﬁnition will be discussed
below.
Pseudoexon inclusion
The observation that consensus splice site sequences are
also very abundant in intronic sequences indicates that introns
have the potential ability to encode for ‘false’ exons
(commonly referred to as pseudoexons) (64,66). Pseudoexons
insertion in mature mRNA have been mainly reported in
connection with human diseases and Table 1 shows a
Figure 3. (A) This figure shows the effect on internal intron retention in exon 6 of the TPO gene. When the TPO gene is transfected in Hep3B cells only two
processed mRNAs are produced, a major form lacking all the intervening introns (74%) and a minor form in which there is the removal of an additional 116 nt
long sequence (26%) from the processed mRNA (upper panel, boxed in red). On the other hand, lower panel shows that when the TPO cDNA is transfected in
Hep3B cells no processing of this internal intron can be observed. (B) The only way of recovering internal intron processing is that of reintroducing at least one of
the normally processed introns of the TPO gene. An analogous situation in which the system has to be ‘primed’ before it can function efficiently is provided by
the recent observation that coordinated splicing can occur in correspondence of distant alternatively spliced exons. (C) Shows such an experiment where two
alternatively spliced EDA exons (pEDA and dEDA) separated by a 3400 nt long spacer containing three constitutively spliced exons are inserted in a minigene
systems in either wild type or mutated form (lacking an important ESE sequence). The graph on the left shows that efficient inclusion of the proximal exon
strictly correlates with inclusion efficiencies of the distal exon.
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been described. Nonetheless, and possibly more important
from a biological point of view, pseudoexon insertion may
well represent a substrate for the evolution of new exons.
Indeed, it has been proposed recently that ‘exonization’ of
a class of particularly abundant intronic sequences (known
as Alu repeats) may well represent a major and frequent
source of ‘new’ exons and thus play a very important and use-
ful role in evolution (103–105).
Despite the abundance in the genome of potential pseu-
doexons (intronic sequences between 50 and 200 nt in length
with apparently viable 50ss and 30ss sites at either end) their
inclusion does not seem to be a frequent event during normal
pre-mRNA processing. Several different reasons have been
put forward to account for this, e.g. it was originally noted
that many of these ‘non-spliced’ pseudoexons contain multi-
ple defects in splicing controlling regions despite their appar-
ently good agreement with real exonic sequences (64). In
keeping with this, three putative splicing silencer motifs
have been found recently to be enriched in these non-spliced
pseudoexons compared with their surrounding intronic
regions (66). This observation is consistent with previous
work which showed that human DNA is particularly rich in
sequences which can inhibit splicing (65). Furthermore,
an extended computational analysis of 8mer sequences that
either promote or inhibit splicing in internal non-coding
exons versus non-spliced pseudoexons has revealed that
enhancer sequences are highly enriched in real exons whilst
silencer sequences tend to cluster within pseudoexons (67).
Finally, computational studies have suggested recently that
pseudoexons ﬂanking regions have a distinct tendency to
form double-stranded structures that include the pseudo
exon itself, providing an additional layer that differentiates
them from real exons, where ﬂanking regions have the
tendency to base pair between themselves (106).
Nonetheless, many intronic sequences seem poised on the
brink of becoming exons because, as shown in Table 1, most
of these disease-connected pseudoexon inclusion events
originate from a single activating mutation. This mutation
generally involves the ex novo creation of a strong donor or
acceptor site, followed by the subsequent selection of weaker
‘opportunistic’ acceptor or donor site sequences. However,
other mechanisms that cause the inclusion of pseudoexon
sequences may also take place, and pseudoexon-activating
mutations may also involve the creation/deletion of SREs.
There are in fact at least two cases, in the a-Gal A (107)
(Figure 4A) and the ATM gene (108) (Figure 4B), in which
the creation/deletion of SREs has been observed to occur.
In the ATM gene the inclusion of a 65 nt long pseudoexon
is the consequence of a 4 nt deletion in ATM intron 20 that
disrupts a high-afﬁnity U1snRNP-binding site located within
the pseudoexon sequence itself. This region was called ISPE
(intron splicing processing element) and its disruption
resulted in the activation of an immediately upstream cryptic
acceptor site and of a downstream cryptic donor site (108).
The comparison of this intronic sequence with its homolog-
ous region in the mouse has shown the importance of local
context also in this case. In fact, an ISPE sequence is also pre-
sent in the mouse and only a critically missing donor site
downstream of this element is the reason why the mouse
sequence cannot give rise to an analogous pseudoexon inser-
tion event (109).
It is interesting to note that in recent years a lot of effort
has gone into deciphering the code that underlies alternatively
spliced exon recognition (29,53,69). However, the recent
increase in pseudoexon and intron retention events reported
in clinical investigations indicates that we should focus also
on deciphering splicing codes within introns. In fact, investi-
gations on pseudoexons may well acquire a wider importance
in the future, as it has also been proposed recently that many
of the these sequences which are thought to be ignored by the
splicing machinery also participate in splicing regulation pro-
cesses (110). The interesting notion is that the functional
usage of many of these putative pseudoexon sequences may
be often overlooked owing to the fact that their inclusion
can lead to premature insertion of a termination codon in
the mature mRNA, and its consequently rapid degradation
by the nonsense-mediated decay (NMD) pathway (111).
This intriguing phenomenon has been described to occur in
the rat a-tropomyosin gene in which a pseudoexon sequence
localized downstream of the mutually exclusive exons 2 (that
is included only in smooth muscle tissue) and 3 (that is
included in most cell types) can give rise to different splicing
outcomes when it is joined to either exon (110) (Figure 4C).
In particular, when joined to exon 2 the formation of an efﬁ-
cient ZLE (zero length exon) sequence allows to resplice
exon 2 to the acceptor site of exon 4 (thus giving rise to a
normally processed mRNA molecule). On the other hand,
when the pseudoexon sequence is joined with exon 3 the
resulting ZLE is not sufﬁcient for the resplicing pathway
and the pseudoexon 50ss is used to join with the acceptor
site of exon 4 (thus giving rise to a mRNA molecule which
is rapidly degraded by NMD.
Table1. list of pseudoexon inclusion events connectedwith disease in humans
Gene Pseudoexon
length (bp)
Activating
mutation
Reference
DMD 58 50ss creation 182
DMD 67 50ss creation 183
DMD 89 50ss creation 183
DMD 90 50ss creation 183
DMD 95 30ss strengthening 182
DMD 149 30ss creation 183
DMD 172/202 50ss creation 184
CFTR 49 50ss creation 185
CFTR 84 50ss creation 186
CFTR 184 30ss deletion 187
CFTR 214 50ss creation 188
CYBB 56 50ss strengthening 189
CYBB 94 30ss creation 190
PHEX 50/100/170 50ss creation 191
a-Gal A 57 SRE creation 107
ATM 65 SRE deletion 108
BRCA1 66 30ss creation 192
GHER 69 50ss creation 193
CHM 98 30ss creation 194
GHR 102 50ss creation 195
ATM 137 50ss creation 196
OA1/GPR143 165 30ss creation 197
b-globin 165 50ss creation 78
NF-1 172 30ss creation 198
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A practical example of the importance of genomic context on
the splicing process is represented by the splicing regulation
of the neuroﬁbromatosis type-1 (NF-1) exon 37 (112).
This exon is localized in an exon-rich genomic cluster
(Figure 5A) and mutations within its sequence have been
shown to be involved in the development of neuroﬁbromato-
sis (113). It has been shown recently that this exon is badly
recognized by the splicing machinery if it is placed with
limited ﬂanking intronic sequences in a minigene with het-
erologous genomic context. However, it becomes efﬁciently
recognized when located within its natural milieu in the
region spanning NF-1 exons 34-38 (Figure 5B). Interestingly,
mutations disrupting a SRE sequence within this exon
(including some that have been described in neuroﬁbro-
matosis patients such as C6792G) have genomic context-
dependent effects (112). In fact, analysis of patient’s
lymphoblasts has revealed that this mutation causes both
the skipping of exons 36–37 together and the skipping of
exon 37 alone. Also in this case, the use of a minigene system
to mimick these effects has shown that, after taking in con-
sideration the contribution of the unmutated allele in the
patient’s lymphoblasts, increasing the genomic context to
comprise exons 31–38 allows to duplicate almost exactly
the patient’s in vivo splicing pattern (Figure 5C).
To complicate matters further, it has been observed that
whether an exon is recognized as such and to what an extent
is also decided by the overall architecture of the pre-mRNA.
Two models exist in mRNA processing, the exon deﬁnition
model and the intron deﬁnition model where, as their
names suggest, in the former the exon is deﬁned by the accep-
tor and donor sites that ﬂank it whilst in the latter it is the
acceptor and donor sites on the same intron which deﬁne
its recognition (114,115). Recent experimental evidence has
allowed to determine that intron recognition ceases to occur
when the intron size increases beyond the 200–250 nt range
(116). As splice site recognition across introns of similar
Figure 4. Shows several factors that determine pseudoexon inclusion aside the simple creation of ex novo functional splice sites. In the a-GalA gene (A), a single
point mutation G > A observed to occur in position-4 with respect to a cryptic donor site has the effect of creating a novel A/C rich enhancer element that causes
inclusion of a 57 bp. pseudoexon in the processed mRNA. In a second example, a 4 nt deletion (GUAA) in the intronic region of the ATM gene between exons 20
and 21 caused the insertion of a 65 nt long pseudoexon in the final mRNA (B). Functional analysis has demonstrated that this deletion abolished binding of an
U1snRNP molecule in this position and activated a 30ss lying 12 nt upstream of this element. Finally, (C) shows the effect of the inclusion of a pseudoexon
sequence in the a-tropomyosin pre-mRNA with respect to two mutually exclusive exons 2 and 3. When the pseudoexon sequence (red box) is spliced to exon 2 a
50ss ZLE sequence is regenerated, thus allowing splicing to occur again giving rise to a normal transcript bearing exon 2 joined to exon 4 (upper panel). On the
other hand, when the pseudoexon is joined to exon 3 the ZLE sequence that is regenerated is insufficient to promote joining together of exon 3 to exon 4 and the
resulting transcript is thus degraded by NMD (lower panel). This difference in resplicing activity has been proposed to be consistent with the match to consensus
of the two ZLE elements (higher for exon 2 than exon 3) and for the higher exon spicing enhancer activity of exon 2.
3500 Nucleic Acids Research, 2006, Vol. 34, No. 12size to exons tends to be signiﬁcantly more efﬁcient than
across the exons (116), it follows that exonic sequences
with similar exon/intron junction sequences can be recog-
nized with widely different efﬁciencies depending on the
local pre-mRNA architecture where they happen to be
present.
SREs ADD A LAYER OF REDUNDANCY FOR THE
DEFINITION OF WEAK SPLICE SITES
The ﬁrst observation that exonic sequences were modulating
alternative splicing in a cellular gene was done in 1987 (117).
At that time this observation appeared to most researchers
as an exceptional case, difﬁcult to interpret. However, in
the last 10 years it has been shown that far from being
exceptional the presence of SREs in exonic sequences is
the rule and their importance in the modulation of pre
mRNA processing is now widely recognized.
These SREs reinforce the limited information in the splice
sites and, depending on their position of and their effect
on splicing, have been generally classiﬁed as exonic
splicing enhancer and silencer (ESE/ESS) or intronic splicing
enhancer and silencer (ISE/ISS) sequences (Figure 1).
Although the number of reported proteins recognizing
speciﬁc enhancer and silencer elements is steadily growing
(118), most enhancer sequences have been found to bind
members of the SR protein family (119–125) whilst many
silencing elements have been found to bind members of the
hnRNP protein family (55,126–128). There are, however,
several difﬁculties when trying to evaluate the action and
the presence of SREs in many splicing events.
Figure 5. (A) Shows a schematic diagram (drawn to scale) of the exon-rich genomic region surrounding exon 37 of the neurofibromatosis (NF-1) gene. This exon
is normally included constitutively in the mature mRNA but in the presence of a pathological substitution in position 6792 (a C is replaced by a G) the analysis
from patient lymphoblasts reveals both the double skipping of exons 36 and 37 and also skipping of only exon 37. The influence of the genomic context has been
tested by engineering a series of minigene constructs that gradually included larger portions of this genomic region, and their functionality compared with the
in vivo pattern. (B) Wild-type exon 37 alone with a small portion of flanking intronic regions is not sufficient to yield the observed >99% inclusion in normal
lymphoblasts. However, this result can be readily achieved when larger portions of this genomic region are included in the genomic construct. In addition to the
normal situation, an increased genomic context also provides a closer correspondence with regards to the exon skipping effects of the C6792G substitution (C).
In fact, only the construct carrying most of the NF-1 exons 31 to 38 together with a mutated exon 37 yields a percentage of normal transcript, exon 37 skipping
and exon 36–37 skipping that reflects the observed percentage in a patient’s lymphoblasts that carry the C6792G substitution (the asterisk indicates the levels of
normal mRNA from the C6792G-carrying allele after deducting the estimated contribution of the un mutated allele).
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the rough division stated above. For example, classical SR
proteins have also been described to be involved in splicing
repression in a few number of cases (129–131) and some
members of this protein family (SRp38) act as splicing
repressors upon dephosphorylation (132,133). Analogously,
some well-represented hnRNP proteins (hnRNP L) may
also act as splicing enhancers (134) whilst others, such as
hnRNP H, may be involved either in splicing repression or
enhancement depending on context (46,135,136). Hence,
the simple belonging to a particular family of splicing factors
is not a guarantee of function conservation and experimental
studies are often required to clarify the role played by even
well known splicing factor found in new systems under study.
Secondly, the RNA-binding sequences of many of these
splicing factors can be highly degenerate, making it difﬁcult
to spot them beforehand on the basis of the primary sequence
alone. For example, SELEX analysis of SR protein-binding
motifs showed that the major family members recognized
fairly degenerate consensus sequences varying from 5 to
7 nt (137) and, although this ﬁnding is entirely consistent
with the great diversity of ESE sequences mapped within
exons (119,138,139), it obviously provides an additional
hurdle when trying to identify likely binding sites. To these
difﬁculties it has to be added that much of the same problems
apply when investigating common splicing inhibitors, such
as hnRNP A1 (140). Moreover, it has to be noted that local
context factors, such as RNA secondary structure, may pro-
foundly inﬂuence the way that optimal binding motifs are
recognized by their speciﬁc binding factors (141). Therefore,
the simple presence of a high-score-binding motif may not
necessarily translate in a strong binding afﬁnity.
In order to obviate to these difﬁculties several computa-
tional approaches have been proposed based on functional
SELEX methodologies to identify potential SR protein-
binding sites (142), on statistical analysis of genomic exonic
sequences to identify splicing-enhancing sequences (67,
68,143,144), or on the information content of the splice site
sequences (145). The reason why so much effort is devoted
to the development of faster and more efﬁcient ways of
predicting SRE presence/action is justiﬁed by the clear indi-
cation that disruption/creation of these elements has become a
very prominent cause of splicing related alterations in disease
(4). Indeed, it is probable that many mutations which were
previously thought to be harmless polymorphisms may in
reality be very powerful modiﬁers of normal splicing
processes (10,146–148).
At present, the accuracy of these methods to successfully
predict changes in binding of splicing factors has yielded in
some cases encouraging results (143,149,150). However,
in several genes such as dystrophin (151), CFTR (147,148)
and ATR (152) the predictive power of these in silico
approaches has failed to establish a clear connection between
splicing and abolishment (or creation) of SREs. Thus, experi-
mental validation of predictions is still a mandatory step in
most splicing studies. Nonetheless, because of the realization
that accurate in silico approaches will be very useful in
the diagnostic and therapeutic ﬁeld (34,35), studies of this
kind are destined to increase. Indeed, statistical approaches
have also been aimed recently at characterizing inhibitory
sequences (66,69,153) or other kinds of repeated motifs
such as UAGG or G-runs which are often found near or
within alternatively spliced exons and which may contribute
heavily to inclusion/skipping decisions by the splicing
machinery (153,154).
Finally, the mechanisms through which splicing factors
bind SRE sequences has been the subject of many studies,
especially regarding the interplay between classic antagonis-
tic factors such as ASF/SF2 (a SR protein family member that
promotes inclusion) and hnRNP A1 (a classic hnRNP protein
that has been historically associated with exon skipping)
(155,156). In many instances, however, the number of
‘duelling partners’ increases considerably and a complex
number of SRE sequences and binding factors is involved
in regulating tissue- or developmentally speciﬁc alternatively
spliced exons. A schematic diagram of four well-studied
regulatory mechanisms is shown in Figure 6. The example
given are the c-src exon N1 (157,158) (Figure 6A), the
CD44 exon v5 (159–161) (Figure 6B), chicken cTNT exon
5 (162) (Figure 6C) and HipK3 ‘T’ exon (163) (Figure 6D).
In all four cases it should be noted that in order to achieve
tissue- and/or temporal-precise accuracy a complex arrange-
ment of cis-acting elements (with either positive or negative
inﬂuence on exon recognition) is complemented by a
correspondingly high number of splicing factors.
SPLICE SITE STRENGTHS CAN EITHER MASK
OR UNCOVER ADDITIONAL SPLICING
REGULATORY REGIONS PRESENT IN EXONS
A well-studied working example in which the interplay
between splice sites and regulatory sequences has been ana-
lyzed in depth is represented by exon 7 in the SMN1/SMN2
genes. This exon plays a key role in a common autosomal
recessive disorder, spinal muscular atrophy. In humans,
there are two copies of the SMN gene, named SMN1 and
SMN2, and inactivation of the SMN1 gene leads to disease
because the SMN2 gene cannot compensate for its absence.
The reason for this is a critical C to U substitution in exon
7 of the SMN2 gene that does not change the codon but either
disrupts an ASF/SF2-binding site (149,164), creates an
hnRNP A1-binding site (165), or both (although recent evi-
dence supports the ASF/SF2 model whilst conﬁrming an
indirect role for hnRNP A1 in splicing repression). As a result
of this substitution, the SMN2 gene produces a transcript
where exon 7 is predominantly skipped, leading to the pro-
duction of a truncated protein and inability to compensate
for SMN1 inactivation. In addition to this region, several
other SRE sequences both within the exon and in the
upstream intron have been identiﬁed. These elements include
a Tra2-binding site in the region adjacent to the SF2/ASF
interaction (166) and a highly structured ISE region in the
IVS7 intron a short distance away from the donor site (167)
(Figure 7A). Recently, Singh et al. (168) have used a func-
tional selection technique with the aim of identifying addi-
tional controlling elements that regulate the splicing of an
entire exon. As shown in Figure 7B, they have achieved
this purpose by engineering a pre-mRNA template which
contained the full sequence of SMN exon 6 and 8 with
some intronic sequences and a partially randomized (30%)
exon 7 sequences in order to substantially preserve the
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allow mutability of each nucleotide. This pool of pre-
mRNA molecules was then transfected in a human cervical
carinoma cell line and the spliced products were puriﬁed to
select the exon 7 sequences that displayed correct recognition
by the splicing machinery (Figure 7B). After successive
rounds of in vivo selection the different exon 7 sequences
were subsequently analyzed to evaluate the range and type
of nucleotide substitutions that had occurred with respect to
the initial wild-type sequence. Beside conﬁrming previous
results with regards to the SF2/ASF and Tra2-binding regions
the results of this analysis allowed the identiﬁcation of two
novel regulatory regions, one near the 30 end of the exon
(30-Cluster) and a conserved CT tract in the middle. Most
importantly, however, the weak 50ss consensus sequence
was also found to represent a critical factor in regulating
SMN exon 7 recognition, as 82% of the spliced exon 7 clones
identiﬁed following the functional SELEX contained a A54G
substitution (Figure 7B). It is interesting to note that this sub-
stitution alone was quite capable of overcoming the negative
Figure 6. Modulation of tissue- and developmental-specific expression of four different exons. (A) Shows that in non-neuronal cells PTB binds to two CU
elements which are located both upstream and downstream c-src exon N1 and form a silencing complex that interferes with the interaction between U1snRNP
bound at the donor site of this exon and U2AF. This complex does not interfere with binding of U2AF with the U1snRNP present at the donor site of exon 3 and
this allows splicing of exon 3 to exon 4, thereby excluding exon N1 from the mature mRNA. On the other hand, in neuronal cells PTB is removed from the CU
elements by an unknown factor ‘X’ in the presence of ATP and exon inclusion is promoted by the SF2/ASF protein binding to this exon (which is also bound by
its antagonistic molecule, hnRNP A1) and by the DCS complex (which contains hnRNP H/F (H/F), KSRP, plus a neuronal form of PTB known as nPTB or WERI
PTB). (B) Shows the Ras signaling pathway-dependent regulation of splicing of the variable v5 exon in the CD44 gene that occurs during T cell activation. In
normal situations the enhancer complex in correspondence to a GAA-rich motif near the donor site of this exon is repressed by a strong hnRNP A1-binding
sequence. During T cell activation, however, the repression can be overcome by either inhibition or displacement of A1 by phosphorylation of Sam 68
(Src-associated in mitosis) and involvement of powerful splicing coactivators such as SRm160. (C) Represents a model of cTNT exon 5 alternative splicing in the
chicken developing heart. In the embryonic cardiomyocite CUG-BP and ETR-3 are expressed at high levels in the nucleus and they bind to the regulatory regions
downstream of exon 5 (MSE2 to MSE4) to promote its inclusion. On the other hand, in the adult cardiomyocite CUG-BP and ETR-3 expression is downregulated
and skipping is favored by PTB and MBNL proteins that are now free to bind on either side of the exon. Finally, (D) contains a model of HipK3 ‘T’ (testis-
specific) differential exon inclusion in both somatic cells and in germ lines. In somatic cells, hnRNP A1 (A1) is principally responsible for the inhibition of
the T exon donor site, probably with some help by hnRNP H (H). This is favored by the fact that in these cells the Tra2b protein tends to be in low amounts and
is mostly phosphorylated. On the other hand, in germ cells Tra2b expression is upregulated and tends to be in its hypo-phosphorylated form whilst hnRNP A1 is
downregulated. This arrangement allows the Tra2b protein to bind in place of A1 and to promote T exon inclusion with the assistance of SF2/ASF and SRp40
which also bind within this exon.
Nucleic Acids Research, 2006, Vol. 34, No. 12 3503effect of several mutations within other conserved elements
such as the ﬁrst position of the exon or single mutations
within the Tra2-binding site (168).
It is also interesting to note that several splice site pre-
diction programs such as MaxEnt, MDD and MM (169),
NNSplice (170) and Spliceview (171) fail to detect a major
improvement in donor site score following the A54G sub-
stitution (Figure 7C). As these programs are normally very
accurate in detecting splice site strength variations the
most likely conclusion is that only the slightly weakening
of exon 7 splice site can ‘highlight’ several sequences that
would normally not be able to inﬂuence its splicing process.
This is consistent with the observation that alternatively
spliced exons possess splice site sequences which are on
average weaker than splice sites belonging to constitutively
recognized exons and stresses the importance of the context
(172). In addition, it has also to be noted that splice site pre-
diction programs may not pick up additional protein–RNA
interactions at the 50 splice site that may substantially con-
tribute in determining its relative strength. For example, in
the NF-1 exon 3 donor site a G-four stretch in correspondence
to the donor site has been identiﬁed as a binding site of
hnRNP H that severely constrained the 50ss sequences that
could vary without disrupting splicing (46).
Nonetheless, the result of SELEX analysis suggests that
many skipping events originating from various mutations
within the exon may be rescued by even small improve-
ments in splice site quality of the affected exon(s). However,
Figure 7. (A) Shows a schematic diagram of the splicing regulatory regions that have been described to affect recognition of SMN1/SMN2 exon 7. Recently,
a functional SELEX analysis has been applied to this whole exonic sequence. (B) Shows the minigene system based on the human SMN gene used for this assay
in which the entire exon 7 is partially randomized. These sequences can then be selected for inclusion in the final spliced products by subjecting them to rounds of
selection in vivo. The borders of this randomized exon are dotted in (B) to indicate the fact that these sequences will not always be used as an exon in this
technique. After each round of selection the spliced exon 7 sequences are recovered by RT–PCR and reinserted in the minigene splicing cassette. This selection
process has allowed the precise mapping, at the single nucleotide level, of all the major determinants involved in the control of exon 7 splicing. Interestingly,
82% of all the final clones contained the same substitution in correspondence to the last position of this exon, and this change was quite capable of overcoming
the effects of other negative regulatory mutations. (C) Shows a comparison of the two donor site strengths (the wild type and the one carrying the A54G
substitution) using a panel of splice site prediction programs.
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tions within SRE elements would probably involve some too
costly and uncertain investments in gene therapy schemes
and, for this reason, alternative targets should be preferred.
INACTIVATION OF STRONG NEGATIVE
ELEMENTS CAN RESCUE SPLICING DEFECTS
ORIGINATING FROM OTHER NEARBY
REGULATORY ELEMENTS
Therefore, in order to optimize therapeutic strategies an
important question that needs to be addressed is the existence
of hierarchical levels between these splicing regulatory
elements, as this may decide which region should be prefer-
entially targeted by the effector molecule of choice. Recently,
the presence of a human-speciﬁc ISS near to the 50ss of
SMN1/SMN2 exon 7 has been described to have analogous
compensatory effects as the A54G substitution (173). Indeed,
Figure 8A shows that the effects of mutating three well-
characterized SRE elements in SMN1 exon 7 (the ﬁrst
nucleotide, the Tra2 binding sequence, and the conserved
tract) can all be overcome by deleting the ISS-N1 sequence
(Figure 8B). In keeping with this result, much the same effect
can be obtained by the deletion of the ISS-N1 region in
the SMN2 sequence that carries the C6U substitution that
abrogates SF2/ASF binding.
Interestingly, an analogous situation has been described
for exon 9 of the CFTR gene. Skipping of this exon is
involved in the occurrence of several forms of cystic ﬁbrosis
depending on the presence of particular polymorphisms in
a (UG)m(U)n repeated motif near to its 30 splice site (174).
Recently, several studies have conﬁrmed that a nuclear
Figure 8. (A) Shows a diagrammatic representation of several positive elements that regulate SMN1/SMN2 exon 7 inclusion. The elements analyzed in this
experiment are the first nucleotide of exon 7 (1G), the Tra2b-binding site (Tra2), the conserved tract in the middle of the exon (ConsTract) and the intronic
splicing enhancer (element-2) in IVS7. Also shown is the dominant ISS element (ISS-N1). The graphical representation underneath shows the levels of exon 7
inclusion following mutation of all of these elements in a suitable minigene construct. Also included are the basal exon 7 inclusion levels from SMN2 exon 7 that
carries a natural C6U substitution. (B) Shows the effect of the same mutations/substitutions when the ISS-N1 sequence has been deleted from the minigene
constructs. An analogous situation which regards the CFTR exon 9 sequence is schematically represented in (C) in which the (UG)m(U)n repeated motif near the
30ss of this exon has been shown to bind a powerful negative regulator of splicing, TDP-43. Several other cis-acting elements are also shown in this diagram: a
CERES element within the exon, a positive polypyrimidine sequence near the 50ss (PCE) that binds TIA-1, and a human-specific ISS in IVS9 that binds members
of the SR protein family. The graph below shows that mutations within these elements are strongly inhibitory with respect to the basal inclusion level on a
TG11T5 background (lane CFTR exon 9). Nonetheless, also in this case the removal of TDP-43 using siRNA technology rescues the effect of all these negative
mutations (D).
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inhibit its inclusion in the ﬁnal mRNA (175–177). However,
in addition to this regulatory sequence several other exonic
and intronic SREs have been described to take part in splicing
regulation of exon 9: a composite exonic regulatory element
of splicing (CERES) (147), a positive polypyrimidine rich
element near to the 50ss that binds the TIA-1 splicing factor
(PCE) (178), and an ISS further down in IVS9 that binds sev-
eral members of the SR protein family (129) (Figure 8C).
Mutations in all these sequences have modulating effects
in CFTR exon inclusion in the mRNA. In particular, the
CERES element identiﬁed by Pagani et al. (129) lies in cor-
respondence to a previously described C1496A missense
mutation (A455E) which should be therefore also considered
a splicing mutation. The recent use of siRNA technology to
knockdown TDP-43 expression (179) has resulted in a gener-
alized improvement in the inclusion of exon 9 even in the
presence of many of these mutations (Figure 8D), demon-
strating that removal of this key inhibitory factor may be a
useful way of repairing negative mutations also in other con-
trolling elements. In this respect, it is important to note that
depletion of this factor has also been described to override
the need for several ESEs and ISEs of Apo AII exon 3
(180). Obviously, knowledge of other critical functions of
this or any other factor is essential before a general inhibitory
approach is used in therapy.
CONCLUDING REMARKS
Taken together, recent results clearly highlight that any pre-
mRNA sequence is embedded with regulatory elements,
some of which may only be uncovered by disrupting muta-
tions or by other facets of mRNA synthesis (such as transcript
elongation rates or secondary structure). The practical conse-
quences of such an arrangement is that many splicing events
are the result of a ﬁne ‘balance of power’ between a myriad
of controlling factors which can vary from tissue to tissue,
during development or in the presence of external stimuli.
Moreover, the recent discovery that snoRNAs can also par-
ticipate actively in the regulation of splicing (181) empha-
sizes that we are still ignorant of entire classes of splicing
regulators. This complexity makes the job of predicting the
splicing outcomes of given genomic variations exceedingly
difﬁcult for the researcher. Nonetheless, not all these factors
possess the same weight when determining splicing out-
comes, and the SMN1/SMN2 exon 7 and CFTR exon 9 exam-
ples demonstrate that identifying master checkpoints may, if
acted upon, compensate for negative effects in several other
regulatory elements. This conclusion provides a considerable
encouragement towards the search for novel therapeutic strat-
egies aimed at covering as great an amount as possible of
splicing mutations. Paradoxically, though, it is very probable
that effective cures for many splicing mutations will be
developed long before the functional mechanisms that under-
lie them may be satisfactorily explained.
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